The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature

References

• International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–790.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206.
   PubMed Web of Science ®Google Scholar
• Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discov Med. 2011;11:115–123.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Stauder R, Eichhorst B, Hamaker ME, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an International Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017;28:218–227.
   PubMed Web of Science ®Google Scholar
• Foà R, Del Giudice I, Cuneo A, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014;89:480–486.
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–87.
   PubMed Web of Science ®Google Scholar
• Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92:375–380.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323:720–724.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations with other biomarkers and clinical impact: a retrospective study on behalf of Eric. Haematologica. 2017;102:170.
   Web of Science ®Google Scholar
• Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007;21:2442–2451.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Ruppert AS, Heerema NA, et al. Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. Br J Haematol. 2012;159:82–87.
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107:742–751.
   PubMed Web of Science ®Google Scholar
• Heerema NA, Muthusamy N, Ruppert AS, et al. Prognostic significance of cytogenetic complexity and del(17p) at diagnosis of chronic lymphocytic leukemia (CLL). Blood. 2013;122:1321.
   Web of Science ®Google Scholar
• Baliakas P, Puiggros A, Xochelli A, et al. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica. 2016;101:e299–e302.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact. Blood. 2019. DOI: 10.1182/blood-2018-09-873083.
   PubMed Web of Science ®Google Scholar
• McGowan-Jordan J, Simons A, Schmid M. ISCN 2016: an international system for human cytogenomic nomenclature (2016). Basel, Paris: S. Karger, AG; 2016.
   Google Scholar
• Stölzel F, Mohr B, Kramer M, et al. Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer J. 2016;6:e386.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Robèrt K-H, Öst Å, et al. Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood. 1985;65:134–141.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Robèrt KH, Friberg K, et al. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. Blood. 1980;56:640–647.
   PubMed Web of Science ®Google Scholar
• Han T, Ozer H, Sadamori N, et al. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. N Engl J Med. 1984;310:288–292.
   PubMed Web of Science ®Google Scholar
• Oscier DG, Fitchett M, Hamblin TJ. Chromosomal abnormalities in B-CLL. Nouv Rev Fr Hematol. 1988;30:397–398.
   PubMedGoogle Scholar
• Oscier DG. Cytogenetic and molecular abnormalities in chronic lymphocytic leukemia. Blood Rev. 1994;8:88.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Knuutila S, Zeigmeister B, et al. Trisomy 12 in B-cell chronic lymphocytic leukemia: correlation with advanced disease, atypical morphology, high levels of SCD25, and with refractoriness to treatment. Leuk Lymphoma. 1995;19:289.
   PubMed Web of Science ®Google Scholar
• Dierlamm J, Michaux L, Criel A, et al. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogen. 1997;94:27–35.
   PubMed Web of Science ®Google Scholar
• Bigoni R, Cuneo A, Roberti MG, et al. Chromosome aberrations in atypical chronic lymphocytic leukemia: a cytogenetic and interphase cytogenetic study. Leukemia. 1997;11:1933–1940.
   PubMed Web of Science ®Google Scholar
• Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003;121:287–295.
   PubMed Web of Science ®Google Scholar
• Geisler C, Jurlander J, Bullinger L, et al. Danish CLL2‐Study revisited: FISH on a cohort with a 20‐yr follow‐up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia. Eur J Haematol. 2009;83:156–158.
   PubMed Web of Science ®Google Scholar
• Van Dyke LD, Werner L, Rassenti LZ, et al. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol. 2016;173:105–113.
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000;95:999–1006.
   PubMed Web of Science ®Google Scholar
• Heerema NA, Byrd JC, Dal Cin PS, et al. Stimulation of chronic lymphocytic leukemia (CLL) cells with CpG oligodeoxynucleotide (ODN) gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC)h study. Cancer Genet Cytogen. 2010;203:134–140.
   PubMedGoogle Scholar
• Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009;23:117–124.
   PubMed Web of Science ®Google Scholar
• Brejcha M, Stoklasová M, Brychtová Y, et al. Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis. Leuk Res. 2014;38:170–117.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Iskas M, Gardiner A, et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol. 2014;89:249–255.
   PubMed Web of Science ®Google Scholar
• Puiggros A, Collado R, Calasanz MJ, et al. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletion. Oncotarget. 2017;8:54297–54303.
   PubMed Web of Science ®Google Scholar
• Le Bris Y, Struski S, Guieze R, et al. Major prognostic value of complex karyotype in addition to TP53and IGHV mutational status in first‐line chronic lymphocytic leukemia. Hematol Oncol. 2017;35:664–670.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117:3016–3024.
   PubMed Web of Science ®Google Scholar
• Thompson PA, O'Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121:3612–3621.
   PubMed Web of Science ®Google Scholar
• Kreuzer KA, Furman RR, Stilgenbauer S, et al. Outcome of patients with complex karyotype in a phase 3 randomized study of idelalisib plus rituximab for relapsed chronic lymphocytic leukemia. Blood. 2016;128:192.
   Web of Science ®Google Scholar
• Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103:1511–1517.
   PubMed Web of Science ®Google Scholar
• Rigolin GM, Cavallari M, Quaglia FM, et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood. 2017;129:3495–3498.
   PubMed Web of Science ®Google Scholar
• Rigolin GM, Saccenti E, Guardalben E, et al. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biologic characteristics. Br J Haematol. 2018;181:229–233.
   PubMed Web of Science ®Google Scholar
• Blanco G, Puiggros A, Baliakas P, et al. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016;7:80916–80924.
   PubMedGoogle Scholar
• Collado R, Puiggros A, López-Guerrero JA, et al. Chronic lymphocytic leukemia with isochromosome 17q: an aggressive subgroup associated with TP53 mutations and complex karyotypes. Cancer Lett. 2017;409:42–48.
   PubMed Web of Science ®Google Scholar
• Chapiro E, Lesty C, Gabillaud C, et al. “Double-hit” chronic lymphocytic leukemia: an aggressive subgroup with 17p deletion and 8q24 gain. Am J Hematol. 2018;93:375–382.
   PubMed Web of Science ®Google Scholar
• Herling CD, Klaumünzer M, Rocha CK, et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016;128:395–404.
   PubMed Web of Science ®Google Scholar
• Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123:1647–1657.
   PubMed Web of Science ®Google Scholar
• Fidai S, Sukhanova M, Chiu BCH, et al. TP53 aberrations by FISH in CLL and complex karyotype at transformation predict for worse outcome in diffuse large B-cell lymphoma – Richter transformation: a single institution series of 75 DLBCL-RT cases. Blood. 2018;132:2984.
   Google Scholar
• Rogers KA, Huang Y, Ruppert AS, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018;180:259–266.
   PubMed Web of Science ®Google Scholar
• Miller CR, Ruppert AS, Heerema NA, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017;1:1584–1588.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Jaromin S, Kern W, et al. In depth characterization of CLL with normal karyotype by array CGH and mutation screening. Blood. 2015;126:1707.
   PubMed Web of Science ®Google Scholar
• Gunn SR, Mohammed MS, Gorre ME, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn. 2008;10:442–451.
   PubMed Web of Science ®Google Scholar
• Puiggros A, Puigdecanet E, Salido M, et al. Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescence in situ hybridization techniques? Leuk Lymphoma. 2013;54:986–995.
   PubMed Web of Science ®Google Scholar
• Stevens-Kroef MJPL, van den Berg E, Olde Weghuis D, et al. Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling. Mol Cytogenet. 2014;7:3.
   PubMed Web of Science ®Google Scholar
• Gunnarsson R, Mansouri L, Isaksson A, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica. 2011;96:1161–1169.
   PubMed Web of Science ®Google Scholar
• Leeksma A, Baliakas P, Mellink C, et al. Genomic complexity in chronic lymphocytic leukemia defined by array-based analysis: definitions, associations with other biomarkers and clinical impact. Blood. 2017;130:4280.
   Web of Science ®Google Scholar
• Cavallari M, Cavazzini F, Bardi A, et al. Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. Oncotarget. 2018;9:34398–34412.
   PubMedGoogle Scholar